Overview of CAR T-cell Therapy Options in R/R MM

EP: 1.Clinical Scenario I: 68-yr Old Man with Early Relapse MM

EP: 2.Clinical Insights on Next Treatment Approach Steps

EP: 3.Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

EP: 4.Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

Now Viewing

EP: 5.Overview of CAR T-cell Therapy Options in R/R MM

EP: 6.Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

EP: 7.Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

EP: 8.Clinical Insights on the Patient Presentation & Treatment Course

EP: 9.Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

EP: 10.Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

EP: 11.Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

Video content above is prompted by the following:

• What current CAR T- cell therapy options are there for r/r MM? [EX1]
  • Resource Link: CARVYKTI (cilta-cel) HCP website
  • Reource Link: ABECMA (ide-cel) HCP website
• What are some challenges with CAR T-cell therapy in r/r MM that you’ve experienced in your clinical practice? What are some potential resources and/or strategies to help support logistical challenges or early referral?
• What is the role of bridging therapy prior to CAR T-cell therapy?
  • How do you define “bridging therapy”?
  • What is the potential role of Selinexor as bridging therapy, and how have you incoporated it in your practice?
    • Resource Link: Blood Cancer J 2024 Real-world impact of bridging therapy on ide-cel outcomes US Myeloma Immunotherapy Consortium
    • Resource Links: J Tansl Med 2023 XPO-1 inhibtior may enhance effect of BCMA CART extramedullary rr MM